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Background: If left untreated, vitreomacular traction (VMT) will infrequently improve through spontaneous
resolution of vitreomacular adhesion (VMA), and patients remain at risk of further deterioration in vision.
The mainstay of treatment for VMT is vitrectomy, an invasive procedure that carries the risk of rare but
serious complications and further vision loss. As such, a ‘watch and wait’ approach is often adopted before
this surgical intervention is performed. Ocriplasmin (microplasmin) is a potential alternative treatment for
patients with symptomatic VMA/VMT that may remove the requirement for vitrectomy.
Objective: The purpose of this study was to evaluate the cost-effectiveness of ocriplasmin for the treatment of
VMT in comparison to standard of care.
Study design: A cohort-based computer simulation model was developed, capturing three mutually exclusive
subgroups: 1) VMT without epiretinal membrane (ERM) or full thickness macular hole (FTMH), 2) VMT
with ERM but no FTMH, and 3) VMT with FTMH. Transition probabilities between health states, utilities,
and resource utilisation were estimated based on clinical trial results, the literature, and expert opinion. The
cost per quality-adjusted life year (QALY) gained was estimated over a lifetime, using UK unit costs and
utilities associated with visual acuity, adverse events, metamorphopsia, and surgical interventions.
Setting: Analyses were conducted from a UK payer perspective.
Population: Transition probabilities for the model were primarily estimated from patient-level data from the
combined Phase 3 MIVI-TRUST trials in patients with symptomatic VMA/VMT, including when associated
with a FTMH 5400 mm.
Intervention: Ocriplasmin (microplasmin) is a one-time intravitreal injection designed specifically to release
the abnormal traction between the macula and the vitreous and thereby treat VMT, as well as macular hole
with persistent vitreous attachment.
Main outcome measure: The main outcome measure of the economic evaluation was cost per QALY.
Results: In all subgroups, ocriplasmin management generated more QALYs: 1) VMT without ERM or
FTMH (0.105, (0.036, 0.191)); 2) VMT with ERM but no FTMH (0.041, (0.011, 0.131)); and 3) VMT with
FTMH (0.053, (0.002, 0.113)). The initial treatment costs were partially offset by later savings and net costs
were estimated at £1,901 (£1,325, £2,474), £2,491 (£1,067, £2,511), and £1,912 (£1,233, £2,506), respectively.
Costs per QALY were estimated at £18,056 (£8,241, £64,874), £61,059 (£8,269, £168,664), and £36,250
(£144,788, £290,338), respectively. Short-term efficacy parameters were found to be key drivers of results.
Conclusion: Ocriplasmin is most cost-effective in VMT patients without either ERM or FTMH.
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symptomatic vitreomacular adhesion
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C
linically, vitreomacular adhesion (VMA) refers to
abnormal, persisting vitreous attachment at or
near the fovea, occurring in the context of peri-
foveal separation (1). If VMA applies sufficient tractional
force on the macula, it may distort the macular architec-
ture to cause vitreomacular traction (VMT) or a full-
thickness macular hole (FTMH) (2). Both VMT and
FTMHs can lead to decreased visual acuity (VA) and meta-
morphopsia (2). The prevalence of VMT and FTMHs has
been estimated at 0.02 and 0.15%, respectively (2).
There are several important gaps in the literature of
VMT. Few reports detail the natural history of VMT and
there are no large randomised controlled trials of PPV for
VMT (3, 4). Traditionally there are two main manage-
ment options, pars plana vitrectomy (PPV) or observa-
tion, the latter for stable mild disease that does not justify
the risks of surgery, or in the expectation that in some
eyes VMT will resolve spontaneously. Observation may
have disadvantages, with a natural history study report-
ing that only 11% of eyes showed spontaneous resolution
over a mean follow-up of 5 years, whereas 64% of eyes
lost at least two Snellen lines over this timeframe. VMT
can also progress to FTMH during observation. Patients
who experience persistent or severe symptomology may
undergo PPV. Equally, PPV for VMT may have dis-
advantages, with only one-third of eyes gaining two or more
Snellen lines (3). PPV is associated with postoperative
patient burden and the risk of rare but serious complica-
tions such as endophthalmitis (5). Postoperative retinal
detachment occurs in 2.4% of patients, and 92% of
phakic eyes are likely to develop a cataract within 3
years of PPV (6).
Ocriplasmin (microplasmin) is designed specifically to
relieve VMA and thereby treat VMT, as well as macular
hole (MH) with vitreous attachment. Ocriplasmin enzy-
matically cleaves collagen, fibronectin, and laminin,
leading to vitreous liquefaction and loosening of vitreor-
etinal attachment (7). Following recent trial publica-
tions (ClinicalTrials.gov identifiers NCT00781859 and
NCT00798317), an intravitreal injection of ocriplasmin
has emerged as an alternative treatment for patients with
symptomatic VMA/VMT, including when associated with
a FTMH 5400 mm. The primary outcome of these trials
was non-surgical resolution of VMA at Day 28 after a
single intravitreal injection of ocriplasmin (7). Impor-
tantly, successful anatomic outcomes (VMT resolution
and/or FTMH closure) after treatment with ocriplasmin
reduced the need for surgical intervention (PPV) (7).
Ocriplasmin may thereby be associated with reduced
healthcare costs and quality of life (QoL) burdens.
In the present study, the cost-effectiveness of ocriplas-
min was determined as a treatment for VMT, based on
data from the pivotal ocriplasmin trials (8). Accordingly,
we defined three mutually exclusive subgroups: 1) VMT
without epiretinal membrane (ERM) or FTMH; 2) VMT
with ERM but no FTMH; and 3) VMT with FTMH. The
analyses take a UK payer perspective and are aligned
with economic evaluation guidance from the National
Institute for Health and Care Excellence (NICE) (9).
Methods
An economic model was constructed to simulate a hypo-
thetical cohort of patients over a lifetime. This model
includes estimates of disease progression, as well as the
costs and effects associated with two VMT management
strategies: 1) a single intravitreal injection of 125 mg
ocriplasmin (administered at baseline) and 2) the stan-
dard of care (observation and/or PPV as needed). If
needed, the ocriplasmin management strategy also allows
PPV. This analysis was undertaken after the NICE’s
Health Technology Appraisal of ocriplasmin (10).
The model consists of two components. The first com-
ponent is a short-term decision tree model to simulate
participants from the Phase 3 MIVI-TRUST trials
(6-month duration), categorised according to whether
treatment leads to a successful anatomic outcome (VMT
resolution and/or FTMH closure) (Fig. 1a). Patients with
VMT alone at baseline have a risk of developing FTMH
from persistent VMT. Patients with FTMH at baseline
who achieve resolution of VMT may continue to have
persistent FTMH. MH closure is the key clinical end
point for vision outcomes in patients with FTMH at
baseline. In patients without FTMH, VMT resolution
is the key clinical end point. The anatomical and PPV
components of the short-term model determine the
pathway for patients in the longer term.
The second component of the model begins at the end
of the decision tree, when patients enter a Markov state
transition extrapolation model (Fig. 1b) to estimate long-
term clinical and cost outcomes. This component features
two separate health state sets: 1) disease health states to
track anatomical status and number of vitrectomies, and
2) vision health states to track patient VA  defined by
Early Treatment of Diabetic Retinopathy Study letters
read. In total, there are seven disease health states, in-
cluding death, and six vision health states, most of which
cover a mutually exclusive 10-letter range (approximately
two Snellen lines, considered clinically significant)
(Fig. 1b) (2, 11). For the purpose of this analysis, the
worst vision state (VA6, 535 letters or :6/60) was con-
sidered to represent ‘blindness’ (1). Based on the com-
bined status of treatment success, disease progression,
and PPV at the end of the initial decision tree, patients are
allocated to one disease health state and one vision health
state for the start of the extrapolation (Fig. 1a). Short-
term event transitions can occur after an event such as
successful surgical or pharmacological treatment. Long-
term VA health state decline applies to all patients, with
patients in the VMT resolved states assumed to have a
decline in vision at the same rate as the age-matched
Craig Bennison et al.
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Fig. 1. (a) First component of the model: decision-tree structure and resulting disease health states for the start of the extrapolation. (b)
Second component of the model: disease health states, vision health states, and associated transitions in the Markov extrapolation.
FTMH, full thickness macular hole; VA, visual acuity; VMT, vitreomacular traction.
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general population (12). Patients with unresolved VMT
were assumed to experience a faster rate of VA decline to
reflect the progressive nature of the disease (13).
Both study-eye and non-study-eye VA were tracked
throughout the model. Similarly as applied to patients
with resolved VMT, non-study-eye VA declines over time
at a rate equivalent to that of VA decline in a general age-
matched population (12).
Key assumptions and data sources are listed in detail
in the Supplementary file (Supplementary Table 1) and
are further described below. Overall, the majority of
inputs were obtained through patient-level data analyses
from the MIVI-TRUST trial data. This was complemen-
ted by a systematic literature search and advice from
clinical experts to identify model inputs not obtained
from the trial data. Each vision health state was assigned
a utility value (14). Evidence suggests that overall vision,
and hence QoL, has a stronger relationship with the
better-seeing eye (BSE) than the worse-seeing eye (WSE)
(15). Approximately 70% of patients from the MIVI-
TRUST trials received their injection of ocriplasmin in
the WSE. Therefore, a relationship between the WSE and
QoL (utility) was modelled. A matrix of utility values,
corresponding to each unique BSEWSE combination,
was modelled using study-eye and non-study-eye VA
distributions (Supplementary Table 2). Vision health state
utility values from the literature were assumed to repre-
sent both eyes being in the same VA state (Supplementary
Table 3) (14). Utility values for cases where eyes are in
different VA states were populated according to the
assumption that WSE changes have 30% of the impact
that BSE changes have (Supplementary Table 2) (16).
Disutilities were included in the model for adverse
events (AEs), metamorphopsia, PPV, and cataract (Sup-
plementary Table 3). Drug and procedure AEs (i.e.,
ocriplasmin injection or PPV) considered were retinal
tear, retinal detachment, elevated intraocular pressure
(IOP), vitreous haemorrhage, and cataract. AEs related
to the placebo injection were excluded from the analyses.
Based on expert opinion, patients undergoing PPV
were considered blind in the study eye for 2 weeks for
VMT and 1 month for FTMH. The disutility of meta-
morphopsia was derived from visual function question-
naire data, which was transformed to utility using a
mapping algorithm. Disutilities for retinal detachment,
vitreous haemorrhage, and cataract were based on data
from the literature. Taking into account the pre-surgical
vision loss and cataract recovery, the duration of
cataract-related disutility was assumed to be 6 months
(Supplementary Table 3).
The transition probabilities describing a patient’s
anatomical and PPV status, as well as the risk of adverse
events, were based primarily on the combined Phase
3 MIVI-TRUST trial data (Table 1, Supplementary
Table 3) (7). Trial data were used to estimate the
probability of PPV for VMT, the probability of PPV for
FTMH, the probability of PPV success for FTMH
(defined by anatomical closure of the FTMH), and the
probability of FTMH formation from persistent VMT.
The probability of requiring a second PPV, and its success
rate, were based on clinical expert opinion (17). To
increase statistical power, changes in vision due to
VMT resolution or FTMH closure were assumed to be
equivalent and independent of cause (PPV or non-
surgical). The starting age of the simulated cohort was
72 years and 65.8% were female (18). The economic
evaluation was performed for three mutually exclusive
subgroups, defined by the presence or absence of ERM or
FTMH at baseline, as these are distinct diagnoses with
different treatment goals (7). Eyes with FTMH are
seldom expected to achieve spontaneous FTMH closure;
therefore, the observation period for these patients was
typically shorter than for eyes with VMT.
Costs associated with adverse events consider a com-
bination of Healthcare Resource Group codes (Supple-
mentary Table 3). The cost of raised IOP considers only
treatment costs, which were sourced from the British
National Formulary. The cost of blindness was calculated
as the sum of low-vision rehabilitation, depression, and
hip fracture/replacement costs (19). The cost of PPV
includes the surgical procedure, follow-up visits, and
the recovery burden. A recent UK study estimated that
40.5% of PPVs were combined with cataract surgery (6).
Hence, the cost and QoL impact of cataract surgery
were weighted as such. Unit costs represent 2012 values
(Supplementary Table 3). Both costs and quality-adjusted
life years (QALYs) were discounted at 3.5% per annum
following NICE guidelines.
In order to compare the strategies, a cohort was
simulated through the model assuming treatment with
ocriplasmin and then repeated assuming standard of care
management, followed by PPV as needed. Extrapolations
were based on the anatomical distribution of patients at
6 months (Fig. 1a), which was driven by treatment. The
main outcome measure of the model is the incremental
cost-effectiveness ratio (ICER), expressed as the addi-
tional cost per QALY gained, capturing both the costs
and benefits to the patient.
Scenario analyses were conducted to examine the effect
of several assumptions (Supplementary Table 4). The
impact of key assumptions on the ICER were tested for
the following: 1) maximum time limit for PPVs to occur
into extrapolation phase; 2) immediate PPV for patients
with FTMH; 3) patients with FTMH experience a visual
decline at the same rate as patients with VMT; 4)
alternate published source of utility values; 5) adjustment
of the utility impact of changes in the WSE relative to
changes in the BSE; 6) AE rates for ocriplasmin and PPV;
7) increase of metamorphopsia disutility; and 8) model
time horizon. In addition, distributions were fitted
Craig Bennison et al.
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Table 1. Short-term model inputs and corresponding uncertainty distributions as applied in the sensitivity analyses (5)
I. Short-term model end points (VMT no ERM)
Input
Deterministic
value
95% CI
(low)
95% CI
(high)
(Ocriplasmin short term) Probability of non-surgical VMT resolution by Day 28 29.79% 23.40% 36.90%
(Ocriplasmin short term) Unresolved VA1 patients at 1 month 29.54%
(Ocriplasmin short term) Unresolved VA2 patients at 1 month 40.91%
(Ocriplasmin short term) Unresolved VA3 patients at 1 month 19.70%
(Ocriplasmin short term) Unresolved VA4 patients at 1 month 6.06%
(Ocriplasmin short term) Unresolved VA5 patients at 1 month 2.27%
(Ocriplasmin short term) Unresolved VA6 patients at 1 month 1.52%
(Ocriplasmin short term) Probability of non-surgical VMT resolution at Month 6, having not
had vitrectomy or resolution by Day 28
12.71% 7.30% 20.10%
(Observation short term) Probability of non-surgical VMT resolution by Day 28 7.69% 2.90% 16.00%
(Observation short term) Unresolved VA1 patients at 1 month 34.72%
(Observation short term) Unresolved VA2 patients at 1 month 40.28%
(Observation short term) Unresolved VA3 patients at 1 month 13.89%
(Observation short term) Unresolved VA4 patients at 1 month 8.33%
(Observation short term) Unresolved VA5 patients at 1 month 1.39%
(Observation short term) Unresolved VA6 patients at 1 month 1.39%
(Observation short term) Probability of non-surgical VMT resolution by Month 6, having not
had vitrectomy or resolution by Day 28
10.00% 3.80% 20.50%
II. Short-term model end points (VMT with ERM)
Input
Deterministic
value
95% CI
(low)
95% CI
(high)
(Ocriplasmin short term) Probability of non-surgical VMT resolution by day 28 7.78% 4.20% 12.90%
(Ocriplasmin short term) Unresolved VA1 patients at 1 month 24.68%
(Ocriplasmin short term) Unresolved VA2 patients at 1 month 40.91%
(Ocriplasmin short term) Unresolved VA3 patients at 1 month 18.83%
(Ocriplasmin short term) Unresolved VA4 patients at 1 month 11.69%
(Ocriplasmin short term) Unresolved VA5 patients at 1 month 1.95%
(Ocriplasmin short term) Unresolved VA6 patients at 1 month 1.94%
(Ocriplasmin short term) Probability of non-surgical VMT resolution by Month 6, having not
had vitrectomy or resolution by Day 28
7.30% 3.60% 13.00%
(Observation short term) Probability of non-surgical VMT resolution by Day 28 1.61% 0.00% 8.70%
(Observation short term) Unresolved VA1 patients at 1 month 26.23%
(Observation short term) Unresolved VA2 patients at 1 month 40.98%
(Observation short term) Unresolved VA3 patients at 1 month 24.59%
(Observation short term) Unresolved VA4 patients at 1 month 6.56%
(Observation short term) Unresolved VA5 patients at 1 month 0.00%
(Observation short term) Unresolved VA6 patients at 1 month 1.64%
(Observation short term) Probability of non-surgical VMT resolution by Month 6, having not
had vitrectomy or resolution by Day 28
4.00% 0.00% 13.70%
III. Short-term model end points (VMTMH)
Input Deterministic
value
95% CI
(low)
95% CI
(high)
(Ocriplasmin short term) Probability of non-surgical MH closure by Day 28 40.57% 31.10% 50.10%
(Ocriplasmin short term) Non-surgical MH closure by Month 6, having not had a vitrectomy
or closure by Day 28
17.65% 3.80% 43.40%
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around each parameter (Supplementary Table 3) and
one-way sensitivity analyses and probabilistic sensitivity
analyses were conducted to assess the uncertainty in the
model (Figs. 2ac and 3ac). To test validity, health state
distributions at the end of the trial were compared to the
modelled health state distributions at 6 months (7).
Results
Ocriplasmin was associated with increased QoL. Table 2
presents the discounted costs and QALYs per subgroup.
The cost of the ocriplasmin injection was partially offset
by savings from avoided vitrectomies and reduced inci-
dence of cataracts, adverse events, and blindness. Based
on the assumption that PPV could follow either manage-
ment strategy if the underlying condition(s) did not
resolve, the ocriplasmin-to-standard-of-care ICERs were
£18,056/QALY (£8,241, £64,874), £61,059/QALY (£8,269,
£168,664), and £36,250/QALY (£144,788, £290,338),
for the VMT without ERM or FTMH, VMT with ERM,
and VMT with FTMH subgroups, respectively. All costs,
QALYs, and subsequent ICERs were expressed per
patient over a lifetime period.
Short-term efficacy parameters (non-surgical VMT
resolution or FTMH closure) were key drivers of cost-
effectiveness results because these determined the pa-
tient’s disease health state at the start of extrapolation
and, hence, the course of disease progression throughout
the extrapolation period. Assessing cost-effectiveness
according to three different subgroups resulted in small
sample sizes, which were reflected in the wide confidence
intervals for the treatment efficacy parameters. In Fig. 2b,
the extreme ICER impact when applying the high esti-
mate (top row) is due to that scenario producing negative
incremental QALYs. In all subgroups, the majority of
iterations from the probabilistic analyses demonstrated
increased QALYs with ocriplasmin, but for additional
costs (Fig. 3ac).
Six-monthly health state distributions were comparable
for each subgroup when comparing the model outcomes
with the trial results, supporting the internal validity of
the model (7).
Discussion and conclusion
This study aimed to estimate the clinical and cost-
effectiveness of ocriplasmin for the treatment of three
clinically distinct patient subgroups, namely VMT with-
out ERM, VMT with ERM, and VMT with FTMH.
These subgroups were defined by baseline ocular prog-
nostic factors (the presence or absence of ERM, or
of MH), treatment goals (VMT resolution versus MH
closure), different efficacy profiles of ocriplasmin, and
the expected treatment pathway (ocriplasmin use as an
alternative to surgery, or for ‘watch and wait’ patients
who have severe symptoms but are not eligible for surgery
versus ocriplasmin used during the wait for surgery,
without delaying the surgery).
Ocriplasmin was compared to standard of care in a UK-
based model that used a lifetime horizon to capture long-
term vision changes associated with treatment. The
model incorporated the likelihood of PPV occurring if
the underlying condition(s) did not resolve or symptoms
remained. Ocriplasmin treatment was associated with
higher QALY gains and incremental costs in all three
subgroups when compared to standard of care. Based on
commonly accepted UK cost-effectiveness willingness-
to-pay thresholds of £20,000 to £30,000 per QALY, the
results seen in the VMT without either ERM or FTMH
subgroup were considered highly cost-effective from a UK
perspective (9).
Savings from the avoidance of blindness partially offset
the cost of ocriplasmin in this subgroup. The majority
of QALYs gained are from the lifetime accrual of VA
benefits. Savings from avoidance of vitrectomies and
cataract operations partially offset the cost of ocriplasmin
in the VMT with FTMH subgroup. The QALY gains
Table 1 (Continued )
I. Short-term model end points (VMT no ERM)
Input
Deterministic
value
95% CI
(low)
95% CI
(high)
(Ocriplasmin short term) Probability of non-surgical VMT resolution by Month 6, having not
had MH closure or vitrectomy
50.00% 23.00% 77.00%
(Observation short term) Probability of non-surgical MH closure by Day 28 10.64% 3.50% 23.10%
(Observation short term) Probability of non-surgical MH closure by Month 6, having not had
a vitrectomy or closure by Day 28
25.00% 7.30% 52.40%
(Observation short term) Probability of non-surgical VMT resolution by Month 6, having not
had MH closure or vitrectomy
58.33% 27.70% 84.80%
CI, confidence interval; ERM, epiretinal membrane; MH, macular hole; VA, visual acuity; VMT, vitreomacular traction.
II. Short-term model end points (VMTMH)
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Fig. 2. One-way sensitivity analyses presented as tornado plots for each subgroup: (a) VMT without ERM or FTMH (VMT no ERM);
(b) VMT with ERM (VMTERM); (c) VMT with FTMH (VMTFTMH). CE, cost-effectiveness; ERM, epiretinal membrane;
FTMH, full-thickness macular hole; ICER, incremental cost-effectiveness ratio; VMA, vitreomacular adhesion; VMT, vitreomacular
traction.
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Table 2. Summary of discounted costs and quality-adjusted life year breakdown in patients in each subgroup who received standard of care or ocriplasmin
VMT no ERM VMT with ERM VMT with FTMH
Standard
of care Ocriplasmin Incremental
Standard
of care Ocriplasmin Incremental
Standard
of care Ocriplasmin Incremental
Costs Drug and administration
costs
£0 £2,617 £2,617 £0 £2,617 £2,617 £0 £2,617 £2,617
Vitrectomy and cataract
costs
£977 £725 £252 £1,190 £1,085 £105 £1,754 £1,197 £557
Adverse event costs £188 £154 £34 £212 £208 £4 £329 £239 £90
Monitoring costs £1,040 £1,023 £17 £1,158 £1,277 £119 £656 £701 £45
Blindness costs £1,983 £1,570 £413 £1,703 £1,567 £136 £614 £511 £103
Total £4,188
(£2,705,
£8,928)
£6,088
(£5,273,
£11,317)
£1,901
(£1,325,
£2,474)
£4,263
(£2,455,
£8,891)
£6,755
(£4,688,
£10,441)
£2,491
(£1,067,
£2,511)
£3,353
(£2,187,
£6,863)
£5,266
(£4,360, £8,620)
£1,912
(£1,233,
£2,506)
QALYs Visual acuity state QALYs 7.047 7.130 0.083 7.148 7.179 0.031 7.424 7.456 0.032
Vitrectomy and cataract
disutilitya
0.016 0.012 0.004 0.028 0.025 0.002 0.035 0.024 0.011
Adverse event disutilitya 0.009 0.007 0.002 0.010 0.009 0.000 0.015 0.011 0.004
Metamorphopsia disutilitya 0.066 0.049 0.016 0.074 0.067 0.007 0.024 0.018 0.006
Total 6.956
(5.953,
8.168)
7.062
(5.985,
8.208)
0.105
(0.036,
0.191)
7.036
(5.845,
8.056)
7.077
(5.934,
8.138)
0.041
(0.011,
0.131)
7.351
(6.242,
8.472)
7.403
(6.284, 8.512)
0.053
(0.002,
0.113)
Discrepancies in incremental results are due to rounding. aLess disutility with ocriplasmin treatment compared to standard of care equals positive incremental QALY. ERM, epiretinal
membrane; FTMH, full thickness macular hole; QALY, quality-adjusted life year; VA, visual acuity; VMT, vitreomacular traction.
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in this subgroup were primarily driven by the lower
incidence of surgical interventions. The lack of cost-
effectiveness in patients with ERM is primarily due to low
rates of efficacy in this subgroup (7).
The scenario analyses suggest that the results from this
cost-effectiveness analysis were reasonably robust to
changes in some of the model’s assumptions.
Sensitivity analyses demonstrated that inputs pertain-
ing to short-term clinical outcomes, such as VMT resolu-
tion, FTMH closure, and need for PPV, were key model
drivers across all subgroups. This confirms the validity
of modelling cost-effectiveness by clinically relevant
subgroups based on the presence of ERM or FTMH.
Further investigation of the impact of using alternative
parameters showed that the largest areas of uncertainty
in the VMT without ERM subgroup were related to
the impact of metamorphopsia disutility, VA decline in
unresolved VMT patients, VA-associated utility, and cost
of blindness, with higher estimates reducing the ICER. In
the VMT plus MH subgroup, reduction in the likelihood
of further surgical procedures (MH closure post-PPV)
had the largest increase on the ICER. Similarly, lower
estimates for disutility of metamorphopsia or cataract
and for utility of VA health states increased the ICER.
The MIVI-TRUST trials were designed in line with
FDA requirements. The comparator arm was based on a
placebo injection and/or PPV as needed. This was likely
to bias against ocriplasmin, as an invasive treatment is
Fig. 3. Cost-effectiveness acceptability curves and scatterplots for each subgroup: (a) VMT without ERM or FTMH (VMT no ERM),
(b) VMT with ERM (VMTERM), (c) VMT with FTMH (VMTFTMH). ERM, epiretinal membrane; FTMH, full thickness
macular hole; VMT, vitreomacular traction.
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not part of the current standard of care. The efficacy
results seen in the placebo-injection arm are likely to be
higher than those seen in clinical practice. Therefore, any
potential bias from having to adopt the placebo injection
rather than true observation is working against ocriplas-
min due to a reduced efficacy gap.
The ERM status of the patient was assumed not to
affect the treatment goals or pathways, which may have
increased the uncertainty around cost-effectiveness esti-
mates in this patient population. Excluding ERM from
the modelled treatment pathways may have favoured
ocriplasmin. This is because the model does not account
for the possibility of ERM in otherwise resolved patients
(i.e., those without VMT or MH). Patients with ERM are
less likely to experience visual decline similar to that of the
general population (as assumed for resolved patients), and
they are likely to experience symptoms such as metamor-
phopsia. In addition, the decision to proceed with surgery
may be affected by the symptoms associated with ERM
and its impact on daily living, as well as by the duration of
ERM. On the other hand, the impact of ERM is indirectly
captured within the covariates for visual acuity at baseline
and 6 months, and the alternative option would have been
to increase the complexity of the model as well as the
number of assumptions required.
To our knowledge, the present study is the first health-
economic evaluation comparing ocriplasmin with stan-
dard of care in VMT patients using a state-transition
model, where the decision problem was conceptualised in
terms of disease and vision health states and transitions
among these states, and in terms of other characteristics
relevant to the decision problem, including metamor-
phopsia. State-transition models are appropriate for
decision problems that require a lifetime horizon and are
one of the most widespread modelling techniques in cli-
nical decision analysis and health economic evaluation (20).
Compared to previous ophthalmology models, our
model also tracks patient vision over time with a set of
discrete, mutually exclusive health states defined by VA
(2123). A major strength of our study is that we
explicitly model VA of both the BSE and WSE, allowing
appropriate assignment of utilities. This unique approach
was designed to acknowledge evidence that the BSE has a
stronger relationship with vision-related QoL than the
WSE, whilst simultaneously taking into consideration
that patients injected in their WSE would still derive
some benefit from the treatment (especially in the case
where a WSE becomes a BSE after treatment). Given the
clinical relevance of metamorphopsia as a symptom
in patients with FTMH and symptomatic VMA/VMT,
we also attempted to model the impact of anatomical
outcomes on metamorphopsia and the impact of meta-
morphopsia on QoL (9, 24).
This modelling study followed recommended metho-
dological practices and standards in health economics
(25). Unlike the recent cost evaluation for treatment of
VMA and MHs (26), the first step in our study was to
conduct a systematic review of the literature, which was
needed to populate the model parameters related to
efficacy end points for the comparative treatment op-
tions. A systematic literature review is important to
ensure both treatment options are interchangeable in
the treatment pathway and are used in a population with
similar baseline characteristics, such as baseline level of
disease stage and visual acuity (27). Currently, the single
robust source for randomised prospective evidence is the
MIVI-TRUST clinical trials, which was the primary
source of evidence used in this study.
In conclusion, ocriplasmin therapy produces health-
related QoL benefits when compared with the standard of
care. The results suggest that the cost-effectiveness of
ocriplasmin is highest for VMT without ERM patients.
Following NICE technology appraisal methods and
requirements, the cost-effectiveness estimates predicted
by the current model in patients with VMT with ERM or
Stage II MHs up to 400 microns with persisting VMA are
less certain (as demonstrated in Figure 2), and further
research may be warranted. Cost per QALY thresholds
are country-specific and this model can be adapted for
assessing cost-effectiveness in other countries. If thresh-
olds as calculated by the WHO project Choosing Inter-
ventions That Are Cost-Effective are assumed, the use of
ocriplasmin in patients with VMT alone or with VMT
and FTMH may be considered to be cost-effective (28).
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